Table 2.
AUC (h·ng/mL)a | Cmax (ng/mL)a | tmax (h) | INRAUCa | INRmaxa | |
---|---|---|---|---|---|
Exenatide 10 mcg BID Soon et al. [25] |
S: 1.06 (1.01, 1.11) R: 1.11 (1.06, 1.17) |
S: 0.97 (0.93, 1.01) R: 1.05 (1.00, 1.09) |
S: W 4 (3–6) W+GLP 6 (4–12) R: W 5 (3–12) W+GLP 6 (5–12) |
0.94 (0.93, 0.96) | 0.88 (0.84, 0.92) |
Lixisenatide 20 mcg Liu [31] |
S: 1.03 (0.87, 1.22) | S: 0.81 (0.68, 0.96) |
S: W 1 h W+GLP 8 h |
No effect | No effect |
Albiglutide 50 mg Bush et al. [14] |
S: 0.99 (0.95, 1.03) R: 1.02 (0.98, 1.07) |
S: 0.93 (0.87, 0.98) R: 0.94 (0.89, 0.99) |
S: W 1 h W+GLP 1.5 h R: W 1 h W+GLP 1.5 h |
No effect | No effect |
Dulaglutide 1.5 mg de la Peña et al. [15] |
S: 0.986 (0.959, 1.01) R: 0.989 (0.958, 1.02) |
S: 0.783 (0.737, 0.833) R: 0.857 (0.817, 0.900) |
S: W 2 (1–4) W+GLP 4 (1–24) R: W 2 (1–4) W+GLP 8 (2–24) |
1.02 (1.01, 1.03) | 1.02 (0.977, 1.07) |
Semaglutide 1 mg Hausner et al. [16] |
S: 1.05 (0.99, 1.11) R: 1.04 (0.98, 1.10) |
S: 0.91 (0.85, 0.98) R: 0.93 (0.87, 1.00) |
S+R: W1 h W+GLP 3 h |
1.05 (0.87, 1.28) | 1.04 (0.99, 1.10) |
BID twice daily, Cmax maximum observed plasma concentration, GLP1 glucagon-like peptide 1, INR international normalized ratio, INRmax maximum observed level, R R-warfarin, S S-warfarin, tmax time to maximum observed plasma concentration, W warfarin, W+GLP warfarin administered with a GLP1 receptor agonist
aData are presented as the ratio of the least squares geometric mean (warfarin+GLP1 receptor agonist / warfarin) with a 90% confidence interval for the ratio. The 0.8–1.25 limits are considered for equivalence